Ally Financial Inc. Purchases New Holdings in Becton, Dickinson and Company (BDX)

Ally Financial Inc. purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 5,000 shares of the medical instruments supplier’s stock, valued at approximately $976,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Almanack Investment Partners LLC. acquired a new position in Becton, Dickinson and during the first quarter worth about $105,000. Parkside Financial Bank & Trust boosted its position in Becton, Dickinson and by 1.4% during the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after acquiring an additional 9 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in Becton, Dickinson and by 55.8% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares during the period. Harfst & Associates Inc. raised its stake in Becton, Dickinson and by 46.4% during the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 221 shares during the period. Finally, QCI Asset Management Inc. NY raised its stake in Becton, Dickinson and by 9.2% during the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after purchasing an additional 60 shares during the period. Institutional investors and hedge funds own 86.83% of the company’s stock.

In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the transaction, the insider now directly owns 12,861 shares in the company, valued at $2,538,890.01. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the transaction, the insider now owns 26,638 shares of the company’s stock, valued at $5,279,917.98. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 75,904 shares of company stock valued at $15,242,688. 1.40% of the stock is owned by corporate insiders.

Shares of Becton, Dickinson and Company (NYSE BDX) traded up 0.12% during trading on Friday, reaching $210.10. 1,571,834 shares of the company’s stock were exchanged. The company’s 50-day moving average is $199.26 and its 200 day moving average is $194.48. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $214.72. The stock has a market capitalization of $47.81 billion, a PE ratio of 60.85 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. Becton, Dickinson and’s quarterly revenue was down 5.1% on a year-over-year basis. During the same period last year, the company earned $2.35 earnings per share. On average, analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Ally Financial Inc. Purchases New Holdings in Becton, Dickinson and Company (BDX)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/28/ally-financial-inc-invests-976000-in-becton-dickinson-and-co-bdx-stock.html.

A number of equities research analysts have recently issued reports on BDX shares. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their price objective for the company from $210.00 to $180.00 in a report on Friday, June 30th. Piper Jaffray Companies restated a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Zacks Investment Research cut shares of Becton, Dickinson and from a “hold” rating to a “sell” rating in a report on Monday, October 9th. Bank of America Corporation reiterated a “buy” rating and set a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Finally, Wells Fargo & Company initiated coverage on shares of Becton, Dickinson and in a report on Friday, September 22nd. They set an “outperform” rating and a $225.00 price target for the company. Five investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $205.14.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply